Market Cap 3.29B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 721,600
Avg Vol 1,423,826
Day's Range N/A - N/A
Shares Out 96.48M
Stochastic %K 47%
Beta 0.16
Analysts Strong Sell
Price Target $81.85

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:37 PM
$RARE: Current market context indicates a potential bullish reversal. The RSI of 36.54 suggests that the stock is nearing oversold territory, which could lead to upward momentum. The last close at $34.58 is above the 30-day moving average (MA30) of $34.24 and the 50-day moving average (MA50) of $33.90, indicating a bullish trend. Trade Plan: - Suggested Entry: $34.60 - Stop Loss: $32.50 (approximately 6% below entry) - Take Profit Targets: 1. $36.50 (5.5% gain) 2. $38.00 (9.5% gain) 3. $40.50 (17% gain) The 60-day high of $39.89 provides a strong resistance level, while the low of $28.56 gives a solid support base. With the current price above key moving averages and the potential for upward movement, this trade offers a favorable risk-reward ratio. Monitor closely for market reactions and adjust as necessary. https://privateprofiteers.com
0 · Reply
LAbslug
LAbslug Dec. 24 at 5:51 PM
$RARE $MREO it makes sense not to release data when volume potential is low. Strategically it would make sense to release phase 3 data after Ultra announces they will attend the JPM conference in January. Say, in about 2 weeks from now.
2 · Reply
BioBull88
BioBull88 Dec. 24 at 4:30 PM
$RARE I imagine the phase 3 results will be released before the JPM Conference in January. My guess would be that this will be the lowest we will see the stock because of light volume during the holidays. The 44th Annual J.P. Morgan Healthcare Conference is scheduled for January 12–15, 2026, in San Francisco, California, primarily at The Westin St. Francis Hotel, serving as the industry's leading investment symposium connecting leaders, innovators, and investors across the healthcare sector. Earlier this year: NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.
0 · Reply
LAbslug
LAbslug Dec. 23 at 6:07 PM
$RARE What is taking so long to release phase 3 Sest results? It’s making me nervous.
1 · Reply
AAKSHI9953
AAKSHI9953 Dec. 22 at 8:38 PM
$RARE looks like data coming tomorrow
2 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
Latest News on RARE
Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 4 months ago

Ultragenyx to Participate at Investor Conferences in September


Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 9 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline


Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 10 months ago

Ultragenyx to Participate at Investor Conferences in March


Ultragenyx to Participate in Investor Conferences in December

Nov 26, 2024, 4:30 PM EST - 1 year ago

Ultragenyx to Participate in Investor Conferences in December


Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12, 2024, 11:12 AM EST - 1 year ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:37 PM
$RARE: Current market context indicates a potential bullish reversal. The RSI of 36.54 suggests that the stock is nearing oversold territory, which could lead to upward momentum. The last close at $34.58 is above the 30-day moving average (MA30) of $34.24 and the 50-day moving average (MA50) of $33.90, indicating a bullish trend. Trade Plan: - Suggested Entry: $34.60 - Stop Loss: $32.50 (approximately 6% below entry) - Take Profit Targets: 1. $36.50 (5.5% gain) 2. $38.00 (9.5% gain) 3. $40.50 (17% gain) The 60-day high of $39.89 provides a strong resistance level, while the low of $28.56 gives a solid support base. With the current price above key moving averages and the potential for upward movement, this trade offers a favorable risk-reward ratio. Monitor closely for market reactions and adjust as necessary. https://privateprofiteers.com
0 · Reply
LAbslug
LAbslug Dec. 24 at 5:51 PM
$RARE $MREO it makes sense not to release data when volume potential is low. Strategically it would make sense to release phase 3 data after Ultra announces they will attend the JPM conference in January. Say, in about 2 weeks from now.
2 · Reply
BioBull88
BioBull88 Dec. 24 at 4:30 PM
$RARE I imagine the phase 3 results will be released before the JPM Conference in January. My guess would be that this will be the lowest we will see the stock because of light volume during the holidays. The 44th Annual J.P. Morgan Healthcare Conference is scheduled for January 12–15, 2026, in San Francisco, California, primarily at The Westin St. Francis Hotel, serving as the industry's leading investment symposium connecting leaders, innovators, and investors across the healthcare sector. Earlier this year: NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.
0 · Reply
LAbslug
LAbslug Dec. 23 at 6:07 PM
$RARE What is taking so long to release phase 3 Sest results? It’s making me nervous.
1 · Reply
AAKSHI9953
AAKSHI9953 Dec. 22 at 8:38 PM
$RARE looks like data coming tomorrow
2 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 1:03 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 12:29 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 12:28 AM
0 · Reply
solarpulsee
solarpulsee Dec. 21 at 12:22 AM
0 · Reply
judgeyoung2
judgeyoung2 Dec. 20 at 12:02 AM
$PVLA $AMGN $RARE $MREO these are for later
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:34 PM
$RARE: The last close at $32.84 indicates a potential buying opportunity, as the RSI at 39.21 suggests the stock is nearing oversold territory. The MA30 at $33.9 and MA50 at $33.7 indicate a bearish trend, but the proximity to the 60D low of $27.75 provides a strong support level. Market context shows volatility with an ATR of 1.55, allowing for significant price movement. Given the current metrics, the directional bias leans towards a rebound as it approaches the lower end of its 60D range. Trade Plan: - Suggested Entry: $32.50 - Stop Loss: $30.00 (7.65% risk) - Take Profit Targets: 1. $35.00 (7.65% gain) 2. $37.00 (13.71% gain) 3. $38.50 (17.92% gain) This plan aims for at least a 17% ROI on the third target, capitalizing on potential recovery towards the 60D high. https://privateprofiteers.com
0 · Reply
Braindead83
Braindead83 Dec. 18 at 7:34 PM
$RARE news leak selling or just general biotech? Down 18% on no news in 7 days
1 · Reply
Quantumup
Quantumup Dec. 18 at 11:25 AM
BTIG reiterated $MREO Buy/$6 $RARE $NVS $MRK $PG - SNY RHHBY Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2001613341848989996?s=20
0 · Reply
jaykza
jaykza Dec. 17 at 4:33 PM
$ABEO Talked about longer term potential of ABO-503 and AAV204 Capsid tech but near term, 2 royalty streams are imminent (2027/2028) just as Zevaskyn starts maxing production. That is $RARE San Filippo treatment and $TSHA Rett Syndrome treatment. Look at $TSHA chart. Double in 3 months and up over 3x this year. Probably some potential takeout speculation baking in but also strong optimism on drug approval. Though UX111 will likely flow into EPS earlier (2027), TSHA-102 will be the significantly larger royalty. If you look at the numbers and the probabilities, there's little to no downside and ridiculous upside. $ABEO is a free call option here.
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 4:19 AM
$RARE: Current market context indicates a bullish sentiment as the last close at $34.34 is above both the 30-day MA of $33.85 and the 50-day MA of $33.59. The RSI at 54.75 suggests that the stock is neither overbought nor oversold, indicating potential for upward movement. The 60-day high of $39.89 provides a clear resistance level, while the low of $27.75 establishes a solid support range. Actionable Trade Plan: - Suggested Entry: $34.50 (slightly above last close for confirmation) - Stop Loss: $32.50 (below recent support) - Take Profit Targets: 1. Target 1: $36.00 (4.35% ROI) 2. Target 2: $37.50 (8.70% ROI) 3. Target 3: $40.00 (16.68% ROI) This plan offers a structured approach with a potential ROI exceeding 17% at the third target. Monitor price action closely and adjust stop loss to lock in profits as targets are reached. https://privateprofiteers.com
0 · Reply
mastamind1320
mastamind1320 Dec. 16 at 5:37 PM
$RARE wtf is this 2$ drop on nothing
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:52 AM
$RARE: Current market context shows a strong upward momentum with the last close at $36.23. The RSI at 66.02 indicates that the stock is approaching overbought territory, suggesting a potential pullback. However, the price is above both the 30-day (MA30=33.76) and 50-day (MA50=33.41) moving averages, indicating a bullish trend. Directional bias remains positive as the stock is trading near the 60-day high of $39.89. Given this context, we suggest a trade plan as follows: Entry: $36.50 (slightly above the last close to confirm momentum) Stop Loss: $34.77 (below recent support, approximately 5% risk) Take Profit Targets: 1. $38.00 (5% gain) 2. $39.00 (7% gain) 3. $42.50 (17% gain) This plan aims for a minimum 17% ROI on the third target while managing risk effectively. Execute this strategy with caution, considering market volatility. https://privateprofiteers.com
0 · Reply